Vanguard Global Advisers
TLSI icon

Vanguard Global Advisers’s TriSalus Life Sciences TLSI Stock Holding History

Vanguard Global Advisers’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$69.5K Hold
15,268
– – ﹤0.01% 2948
2026
Q1 		$61.1K Buy
+15,268
New +$74.8K ﹤0.01% 2935

Other funds holding TLSI

FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Cerity Partners
Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WPC
White Pine Capital Bloomington, Minnesota $423M AUM 67.01% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return

Vanguard Global Advisers's TLSI Position: Q2 2026 in Review

Vanguard Global Advisers held its TriSalus Life Sciences (TLSI) position steady in Q2 2026 at 15,268 shares worth $69.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2948.

Vanguard Global Advisers first reported a position in TLSI in Q1 2026 and has held it in 2 quarters since. 78 funds tracked by Wall St. Rank hold TLSI as of Q2 2026.

  • Vanguard Global Advisers held 15,268 shares of TriSalus Life Sciences worth $69.5K as of Q2 2026.
  • Vanguard Global Advisers left its TriSalus Life Sciences share count unchanged in Q2 2026.
  • TriSalus Life Sciences made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2948 holding.
  • Vanguard Global Advisers first reported a position in TriSalus Life Sciences in Q1 2026 and has held it in 2 quarters since.
  • 78 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.